Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – but could struggle to displace rival drugs from Bristol-Myers Squibb and Merck & Co.

Roche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple negative breast cancer, and untreated lung cancer, as the company plays catch-up with Merck ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Study participants first received surgery, followed by the vaccine and Roche's immunotherapy Tecentriq (atezolizumab), and finally chemotherapy. At a median follow-up of 3.2 years, six of the ...

Although many of Roche's older drugs have seen loss of exclusivity, its PD-L1 antibody Tecentriq has been a growth driver, and we think Vabysmo can help Chugai build an ophthalmology portfolio in ...

Roche and Zealand Pharma have formed a potential $5.3 billion collaboration to bring amylin analog petrelintide to market as an obesity treatment, both on its own and in combination with Roche's ...

Tecentriq in combination with bevacizumab will help the 70 or so New Zealanders diagnosed with Hepatocellular Carcinoma (HCC) each year.

and Tecentriq around the decade's end. The analyst further identified a significant near-term risk to Roche's earnings estimates. This risk is associated with the upcoming data from the DB11 trial ...